Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03337022 | Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of CC-90006 in Subjects With Mild to Moderate Plaque-type Psoriasis | PHASE1 | COMPLETED | 34 | — | — | Jan 4, 2018 | Apr 26, 2019 | May 7, 2020 | 4 | United States, Canada |
Number of participants with adverse events
| Arm | Type | Description |
|---|---|---|
| CC-90006; Dose level 1 | EXPERIMENTAL | CC-90006 will be administered subcutaneously (SC) on days 1, 15, and 29. |
| CC-90006; Dose level 2 | EXPERIMENTAL | CC-90006 will be administered subcutaneously (SC) on days 1, 15, and 29. |
| CC-90006; Dose level 3 | EXPERIMENTAL | CC-90006 will be administered subcutaneously (SC) on days 1, 15, and 29. |
| CC-90006; Dose level 4 | EXPERIMENTAL | CC-90006 will be administered subcutaneously (SC) on days 1, 15, and 29. |
| Placebo | PLACEBO_COMPARATOR | Placebo (saline) will be administered subcutaneously (SC) on days 1, 15, and 29. |
| Name | Type | Description |
|---|---|---|
| CC-90006 | DRUG | CC-90006 |
| Placebo | OTHER | Placebo |
Inclusion Criteria: The following is a summary of the inclusion criteria: 1. Males or non-pregnant females between the ages of 18 and 60 years (inclusive) at the time of signing the ICF, and be willing to adhere to the requirements of contraception use throughout the study. 1. Female subjects ...